Technology | April 17, 2015

Cerner and Qualcomm Collaborate on Home Health Monitoring Network

Qualcomm's 2net Platform will capture patient data from home, transmit it via Cerner's CareAware platform

Cerner, Qualcomm, home health monitoring, 2net, CareAware, EHR

April 17, 2015 — Cerner Corp. and Qualcomm Life Inc. announced an agreement to extend Cerner’s medical device connectivity capabilities beyond the hospital to the home. Cerner will leverage Qualcomm Life’s U.S. Food and Drug Administration (FDA)-listed 2net Platform and Hub to capture data from medical devices and sensors within a patient’s home, and transmit it to Cerner healthcare clients through Cerner’s CareAware device connectivity platform. Through this initiative, care providers can remotely monitor chronically ill patients in near-real time to enable proactive engagement to potentially reduce the risk of an acute care episode.

Qualcomm Life’s 2net Platform collects, stores and aggregates patient data from connected medical devices provided to the patient, such as weight scales, blood pressure monitors and pulse oximeters. These data values will transmit via CareAware to the Cerner Millennium electronic health record (EHR) and are viewable to the patient in HealtheLife, Cerner’s patient engagement solution. Extending CareAware to integrate devices within the home to the patient’s EHR will provide healthcare organizations a more comprehensive view in their efforts to focus on chronic condition management, reduce readmissions and improve patient health and satisfaction.

Qualcomm Life will join Cerner’s CareAware certification program, an initiative that creates alliances between Cerner and medical device manufacturers to better acquire data from devices to integrate with the EHR via CareAware device connectivity architecture.

Agnesian HealthCare is one of the first enterprise clients to implement the combined technologies to remotely monitor and manage at-risk patient populations. “It is increasingly important that providers are monitoring the whole health of an individual, not just at the point of care in the facility,” said Michael DeGeer, DPM, FACPS, FACFAS, vice president of population health management, Agnesian HealthCare. “Remote patient monitoring allows our clinicians to have access to patients’ health data, within the patient’s health record, while they are at home, which will provide the opportunity for clinicians to make informed interventions as needed.”

For more information: www.cerner.com, www.qualcommlife.com

Related Content

The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms. #TMVR #TCT2019 #TCT19

The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms.

News | Heart Failure | October 04, 2019
October 4, 2019 – Results of a new economic analysis of the COAPT Trial data found that transcatheter mitral valve re
COAPT Trial three-year data show the MitraClip continued effectiveness in heart failure patients with secondary mitral reguritation. #TCT2019 #TCT19 #mitralclip

COAPT Trial three-year data show the MitraClip continues to show safety and effectiveness in heart failure patients with secondary mitral reguritation.

News | Heart Failure | October 03, 2019
October 3, 2019 – The three-year results from the...
Positive Safety, Efficacy Data Reported on AccuCinch Heart Failure Device
News | Heart Failure | September 27, 2019
Ancora Heart Inc. announced results from an interim analysis of heart failure patients treated in the CorCinch FMR...
Max and Debra Ernst Heart Center Opening at Beaumont Hospital, Royal Oak
News | Heart Failure | September 20, 2019
The new Max and Debra Ernst Heart Center at Beaumont Hospital, Royal Oak, Mich., will open Sept. 30. It is dedicated to...
FDA Grants Fast Track Designation for Farxiga in Heart Failure
News | Heart Failure | September 18, 2019
AstraZeneca announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the...
Corvia Medical and physIQ Partner in Global Phase 3 Heart Failure Device Clinical Trial

The REDUCE LAP HF-II study will combine Corvia Medical's InterAtrial Shunt Device (IASD), pictured here, with physIQ's continuous monitoring platform to evaluate the device's efficacy in patients with heart failure. Image courtesy of Corvia Medical.

News | Heart Failure | September 12, 2019
Corvia Medical has sponsored and is actively enrolling patients in a heart failure (HF) device trial that, in addition...
 Tiny Wearable Cameras May Improve Quality of Life in Heart Failure Patients

Image courtesy of Amazon.com

News | Heart Failure | September 11, 2019
The ever-present devices that seem to track all our moves can be annoying, intrusive or worse, but for heart failure...
PARAGON-HF Misses Endpoint in Preserved Heart Failure
News | Heart Failure | September 11, 2019
The angiotensin neprilysin inhibitor sacubitril/valsartan (Entresto) missed its primary endpoint of reducing total...
Farxiga Significantly Reduces Cardiovascular Death and Worsening of Heart Failure
News | Heart Failure | September 09, 2019
AstraZeneca announced detailed results from the landmark Phase III DAPA-HF trial that showed Farxiga (dapagliflozin) on...
Dapagliflozin, Forxiga, was found to help improve outcomes in heart failure patients with reduced ejection fraction (HFrEF) at ESC 2019. #ESC19 #ESC2019
News | Heart Failure | September 09, 2019
September 9, 2019 — The drug Dapagliflozin was found to reduce death and hospitalization in patients who have heart f
Overlay Init